EyeBio

Eyebiotech Limited (EyeBio) is a privately held ophthalmic biotechnology company dedicated to developing and delivering next-generation therapies to protect, restore, and improve vision for patients with eye diseases. Founded in August 2021 by Dr. David Guyer and Dr. Anthony P. Adamis, EyeBio is led by a team of disruptors in the field of ophthalmic drug development. Operating in the United States and the United Kingdom, EyeBio is building and advancing a portfolio of ophthalmic treatments that combine scientifically robust targets with innovative translational approaches.